Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4%, Teva Pharmaceutical Industries ( TEVA), up 1.9%, Sanofi ( SNY), up 0.9% and Novo Nordisk A/S ( NVO), up 0.9%. On the negative front, top decliners within the industry include Questcor Pharmaceuticals ( QCOR), down 7.8%, Isis Pharmaceuticals ( ISIS), down 5.0%, Intercept Pharmaceuticals ( ICPT), down 3.5%, Shire ( SHPG), down 2.5% and Illumina ( ILMN), down 1.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Celgene Corporation ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene Corporation is up $2.51 (1.6%) to $164.18 on light volume. Thus far, 1.0 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $161.81-$164.20 after having opened the day at $162.55 as compared to the previous trading day's close of $161.67. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene Corporation has a market cap of $65.0 billion and is part of the health care sector. Shares are down 4.3% year-to-date as of the close of trading on Thursday. Currently there are 24 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.